Nanogel Compound

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a novel type of nanogel compound, which is a hydrogel nanoparticle matrix made from specific polymers (like poly(N-isopropylacrylamide) and polyglycerol) that can incorporate either charged components or conjugated polymers. These nanogels can form semi- or interpenetrating networks, and their unique chemical structure makes them highly suitable for stimuli-responsive (especially temperature- and near-infrared (NIR)-responsive) drug delivery. The drug release from these nanogels can be precisely triggered and controlled by external stimuli such as temperature change or NIR laser irradiation, making them particularly useful for targeted and sustained drug delivery, including overcoming drug resistance in cancer therapy.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted anticancer drug delivery, especially for drugs like doxorubicin, paclitaxel, methotrexate, cisplatin, and 5-fluorouracil.
• Stimuli-responsive drug/protein delivery systems for a wide range of diseases.
• Photothermal therapy, where NIR irradiation induces local heating and aids in drug release or tumor ablation.
• Controlled release platforms for sensitive medications that benefit from localized, sustained, or triggered dosing.
• Overcoming multidrug resistance in tumor cells by providing sustained, low-concentration drug delivery that helps avoid efflux mechanisms.
• Combinatorial therapies integrating chemotherapy and photothermal therapy for enhanced cancer treatment.
• Potential applications in gene delivery or protein therapeutics, utilizing the nanogel’s responsiveness and biocompatibility.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly tunable and controllable drug release, responsive to temperature and/or NIR laser irradiation.
• Biocompatible and well-tolerated in vivo, with minimal observed toxicity at effective doses.
• Ability to encapsulate a variety of drugs, including charged and hydrophobic substances.
• Sustained and prolonged release profiles that can be adjusted for specific therapeutic needs.
• Targeted drug delivery reducing systemic toxicity and enhancing therapeutic efficacy, especially in cancer therapy.
• Overcomes drug resistance mechanisms in tumor cells by maintaining effective intracellular drug concentrations.
• Versatility in formulation allows for the development of combination therapies (chemo and photothermal).
• Potential for enhanced treatment efficacy and reduced side effects compared to conventional drug delivery systems.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a nanogel compound comprising a) a nanogel matrix component (2, 3) chosen from the group consisting of poly(N-isopropylacrylamide), poly(N-isopropyl methacrylamide), poly(N,N-diethylacrylamide), poly(N-ethylmethacrylamide), polyglycerol, polyglycerol derivatives and combinations thereof and b) a first (4) or second (5) conjugation component which forms an interpenetrating or semi-interpenetrating network with the nanogel matrix component. Thereby, the first conjugation component (4) is a charged component chosen from the group consisting of acids, methacrylates, methacrylamides, acrylamides and combinations thereof and the second conjugation component (5) is a conjugated polymer chosen from the group consisting of polyaniline, polypyrrole, poly(N-(C1-C10)alkyl aniline), poly(3,4-ethylenedioxythiophene), 2-ethylhexylcyclopentadithiophene-co-2,1,3-benzothiadiazole, 2-ethylhexylcyclopentadithiophene-co-2,1,3-benzoselenadiazole, and combinations thereof.